HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Industry Stained By Criticism Due Irresponsible Firms

This article was originally published in The Rose Sheet

Executive Summary

FDA's warnings to industry "about safety have not always been met adequately or even uniformly accepted," says Steve Tave, director of the agency's dietary supplement programs.

You may also be interested in...



Budget Good For FDA Supplement Sector Oversight? Congress Wants To Know

A report submitted with appropriations legislation negotiated by conference committee and approved by both chambers instructs FDA to report to Congress about its activities and staffing for oversight of supplement manufacturers and marketers. In an indication members are aware of the scope of FDA's responsibilities in the sector, report also asks agency to provide information on work related to "manufacturers and marketers of products claiming to be dietary supplements."

FDA Expects Safety As Ticket To Enter 'Pre-DSHEA' Dietary Ingredient List

FDA agrees with public health advocates that ingredients should be on a potential list of those available when Congress passed DSHEA only after current substantiation for a reasonable expectation of safety for their intended uses.

Lack Of Supplement NDI Notification Guidance Not A Market Pass For Industry

Manufacturers, ingredient suppliers and other parties submitting NDI notifications can improve the industry's outlook by "anticipating future products that haven't been brought to market yet" and proposing the highest concentration of an ingredient for the broadest variety of uses, says ODSP senior advisory Cara Welch.

Related Content

Topics

UsernamePublicRestriction

Register

RS121233

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel